Merck to donate Ebola vaccine candidate for research program in Uganda

(Reuters) Merck said on Tuesday it was planning to produce and donate investigational Sudan ebolavirus vaccine to a global non-profit organization’s research program in Uganda, which is facing an outbreak of the disease. The investigational vaccine that will be donated to IAVI is similar to Merck’s Ervebo vaccine, which is approved against the Zaire ebolavirus strain.